| Oct 9 |
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
|
| Sep 13 |
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
|
| Sep 10 |
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
|
| Sep 9 |
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Sep 8 |
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
|
| Sep 3 |
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
|
| Aug 29 |
C4 Therapeutics to Participate in Upcoming September Investor Conferences
|
| Aug 14 |
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
|
| Aug 3 |
C4 Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 1 |
C4 Therapeutics GAAP EPS of -$0.26, revenue of $12M
|
